@article{11051,
  keywords = {Adolescent, Adult, Age Factors, Aged, Child, Child, Preschool, Dapsone, Drug Therapy, Combination, Evaluation Studies as Topic, Female, Humans, leprosy, Malawi, Male, Middle Aged, Patient Compliance, Rifampin, Sex Factors},
  author = {Boerrigter G and Ponnighaus J M and Fine PE},
  title = {Preliminary appraisal of a WHO-recommended multiple drug regimen in paucibacillary leprosy patients in Malawi.},
  abstract = {<p>A study was undertaken within the framework of the LEPRA Evaluation Project and the LEPRA Control Project in Malawi (Central Africa) to study the incidence rates of type 1 reactions and of relapses in paucibacillary leprosy patients treated with the current World Health Organization-recommended multiple drug regimen (WHO/MDT). Of 503 patients recruited into the study, 488 were reviewed at the end of treatment and 480 have now been followed for 1 year after completion of treatment. At the end of treatment the skin lesions had completely disappeared in 27.4%, but were judged to be still active in 4.3%. During the follow-up period two patients were found with new active skin lesions, giving a relapse rate of 4.17 (2 of 480) per 1000 person years during the first year after completion of WHO/MDT (95% confidence interval 1.14 to 15.06 per 1000 person years). The incidence rate of marked type 1 reaction (renewed inflammation in previously inactive lesions) during the first year after completion of WHO/MDT was 47.8 per 1000 person years in self-reporting patients but zero in patients identified by active case finding. Data are presented which suggest that the incidence rate of late type 1 reactions is closely related to the classification and stage of the disease at detection.</p>},
  year = {1988},
  journal = {International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association},
  volume = {56},
  pages = {408-17},
  month = {1988 Sep},
  issn = {0148-916X},
  url = {http://ila.ilsl.br/pdfs/v56n4a05.pdf},
  language = {eng},
}